Candida albicans Efflux Inhibitor Screening Results from Drug Repurposing Study

A study by Débora Marques, last updated in May 2026, used an in silico drug repurposing approach to identify potential efflux pump inhibitors in the fungal pathogen Candida albicans. The dataset likely contains results from screening 59 drugs, including minimum inhibitory concentrations and adjuvant effects with fluconazole. The work identified amlodipine, fluvoxamine, and fluoxetine as potential efflux inhibitors.

Use Cases

• Identifying drug candidates for combination therapy based on the reported adjuvant effect with fluconazole.
• Analyzing structure-activity relationships for efflux inhibition based on the chemical groups of the 59 screened drugs.
• Validating in silico drug repurposing predictions against in vitro screening results described in the study.
• Prioritizing drugs for further mechanistic studies based on the reported fluorometric assay results for efflux inhibition.

Strengths

• The dataset is associated with a specific, peer-reviewed research methodology described in the summary.
• Results are based on screening 59 drugs selected from an initial set of 777 drugs associated with 51 predicted membrane transport proteins.
• The dataset is licensed under CC-BY-4.0, permitting reuse with attribution.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 32.4 KB, indicating limited scope.

Provenance

Source

figshare, authored by Débora Marques.

Collection Method

Data was generated through an in silico screen of the DrugBank database followed by in vitro screening and fluorometric assays.

Freshness

Last updated 2026-05-18 05:31:28; freshness should be verified.